Skip to main content
Clinical Trials/NCT06625437
NCT06625437
Terminated
Not Applicable

Evaluation of the Effectiveness of Acceptance and Commitment Therapy for General Mental Health Concerns in HIV-Positive Men

University of Alabama at Birmingham1 site in 1 country1 target enrollmentJanuary 15, 2025

Overview

Phase
Not Applicable
Intervention
Acceptance and commitment therapy
Conditions
Stress
Sponsor
University of Alabama at Birmingham
Enrollment
1
Locations
1
Primary Endpoint
Patient Health Questionnaire-9 Screener
Status
Terminated
Last Updated
12 days ago

Overview

Brief Summary

The purpose of the current study is to examine the feasibility and effectiveness of acceptance and commitment therapy, a specific form of cognitive-behavioral therapy, for treating general mental health concerns among HIV-positive men.

Detailed Description

The purpose of the current study is to examine the feasibility and effectiveness of acceptance and commitment therapy, a specific form of cognitive-behavioral therapy, for treating general mental health concerns among HIV-positive men.

Registry
clinicaltrials.gov
Start Date
January 15, 2025
End Date
April 16, 2026
Last Updated
12 days ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nicholas C. Borgogna

Assistant Professor

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • identify as a man
  • be at least 18 years old
  • has been diagnosed with HIV by a healthcare professional

Exclusion Criteria

  • has engaged in self-harm within the last three months
  • has attempted suicide within the last year
  • has had an active plan to attempt suicide within the last 30 days
  • is currently diagnosed with any eating disorder
  • has experienced hallucinations or delusions within the last 30 days
  • has used narcotics within the last 7 days (heroin, meth, crack cocaine, opioids)

Arms & Interventions

Acceptance and commitment therapy

Trial of acceptance and commitment therapy for hiv-positive men.

Intervention: Acceptance and commitment therapy

Outcomes

Primary Outcomes

Patient Health Questionnaire-9 Screener

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of depressive symptoms

PTSD Checklist-5

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of post-traumatic stress symptoms

Yale-Brown Obsessive Compulsive Scale

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of obsessive-compulsive disorder symptoms

Alcohol Use Disorders Identification Test

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of alcohol use

HIV stigma scale

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of facets of stigma experienced by individuals with HIV

Internalized homophobia scale

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of internalized homophobia

Brief pornography screen

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of concerning pornography use

Life Quality Scale

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of life quality

Experiential Avoidance Rating Scale

Time Frame: Administered at baseline, every two weeks (every second therapy session) during intervention, and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of experiential avoidance

National Institute of Drug Abuse Modified Alcohol, Smoking, and Substance Involvement Screening Test

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of drug use

High risk sexual behaviors

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

* Frequency of sex with penetration * Frequency of condom use * Frequency of oral sex * Frequency of sexual partners

Generalized Anxiety Disorder-7 Screener

Time Frame: Administered at baseline and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of anxiety symptoms

PSYFLEX

Time Frame: Administered at baseline, every two weeks (every second therapy session) during intervention, and immediately after final intervention session (8th/final session; each session is 1 hour)

Measure of psychological flexibility

Secondary Outcomes

  • Therapeutic Alliance Scale(Administered immediately after final intervention session (8th/final session; each session is 1 hour))

Study Sites (1)

Loading locations...

Similar Trials